<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CRYSELLE- norgestrel and ethinyl estradiol 
			 </strong><br>Barr Laboratories Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_28b6ec63-d05e-449e-8a37-a16c80052702"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">21 white Cryselle<span class="Sup">®</span> tablets, each containing 0.3 mg of norgestrel, USP (±)-13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one), a totally synthetic progestogen, and 0.03 mg of ethinyl estradiol, USP (19-nor-17α-pregna-1,3,5 (10)-trien-20-yne-3,17-diol), and 7 light-green inert tablets. The inactive ingredients present are hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol and pregelatinized corn starch. The light-green inactive tablets also contain D&amp;C Yellow No. 10 Aluminum Lake, FD&amp;C Blue No. 1 Aluminum Lake and FD&amp;C Yellow No. 6 Aluminum Lake.</p>
<p><span class="Bold">Norgestrel, USP</span></p>
<div class="Figure">
<a name="id463419816"></a><img alt="Norgestrel Strustural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ee6be128-d494-4361-9a0d-341c0eee3587&amp;name=143d035e-f885-4ca9-a37c-b43e26c65aeb-01.jpg">
</div>
<p>C<span class="Sub">21</span>H<span class="Sub">28</span>O<span class="Sub">2                                              </span>MW: 312.45 </p>
<p><span class="Bold">Ethinyl Estradiol, USP</span></p>
<div class="Figure">
<a name="id463419818"></a><img alt="Ethinyl Estradiol Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ee6be128-d494-4361-9a0d-341c0eee3587&amp;name=143d035e-f885-4ca9-a37c-b43e26c65aeb-02.jpg">
</div>
<p>C<span class="Sub">20</span>H<span class="Sub">24</span>O<span class="Sub">2                                                     </span>MW: 296.40 </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_56cfda6f-cbd9-4937-8570-c84ed83167d1"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_8822b29b-6060-44e8-9c4f-4f96b03cb6aa"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Cryselle<span class="Sup">®</span> (norgestrel and ethinyl estradiol tablets USP), 0.3 mg/0.03 mg is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. <span class="Bold"><a href="#_Ref383780760">TABLE 1</a></span> lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization and the IUD, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.</p>
<a name="_Ref383780760"></a><table>
<caption><span>TABLE 1: PERCENTAGE OF WOMEN EXPERIENCING AN <span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">UNINTENDED PREGNANCY</span> DURING THE FIRST YEAR OF USE OF A CONTRACEPTIVE METHOD </span></caption>
<col width="65%">
<col width="13%">
<col width="13%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd><span class="Sup">N/A – not available</span></dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd><span class="Sup">Depending on method (calendar, ovulation, symptothermal, post-ovulation).</span></dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Method</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Perfect Use</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Typical Use</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Levonorgestrel implants</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.05</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.05</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Male sterilization</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.15</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Female sterilization</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Depo-Provera<span class="Sup">®</span> (injectable progestogen)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Oral contraceptives</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     Combined</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">NA<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     Progestin only</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">NA<a href="#footnote-1" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">IUD</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     Progesterone</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     Copper T 380A</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Condom (male) without spermicide</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">14</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     (female) without spermicide</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">21</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Cervical cap</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     Nulliparous women</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     Parous women</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">26</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">40</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Vaginal sponge</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     Nulliparous women</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     Parous women</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">40</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Diaphragm with spermicidal cream or jelly</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Spermicides alone (foam, creams, jellies, and vaginal suppositories)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">26</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Periodic abstinence (all methods)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 to 9<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">25</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Withdrawal</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">19</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">No contraception (planned pregnancy)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">85</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">85</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_d460b877-5558-4400-976b-2778fa9735a0"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Oral contraceptives should not be used in women with any of the following conditions:</p>
<p><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> or thromboembolic disorders</p>
<p>A past history of deep vein <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> or thromboembolic disorders</p>
<p>Cerebral-vascular or <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span></p>
<p>Known or suspected carcinoma of the breast</p>
<p>Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia</p>
<p>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></p>
<p><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span> of pregnancy or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> with prior pill use</p>
<p><span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">Hepatic adenomas</span> or carcinomas</p>
<p>Known or suspected pregnancy</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_e7ecba4d-3c65-474f-b330-3841c25c9719"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<table>
<col width="98%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Cigarette smoking increases the risk of serious cardiovascular side effects from oral-contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.</span></p></td></tr></tbody>
</table>
<p class="First"></p>
<p>The use of oral contraceptives is associated with increased risks of several serious conditions including <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">hepatic neoplasia</span>, <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>, and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span>, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. </p>
<p>Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks.</p>
<p>The information contained in this package insert is based principally on studies carried out in patients who used oral contraceptives with higher formulations of estrogens and progestogens than those in common use today. The effect of long-term use of the oral contraceptives with lower formulations of both estrogens and progestogens remains to be determined.</p>
<p>Throughout this labeling, epidemiological studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control studies provide a measure of the relative risk of disease, namely, a ratio of the incidence of a disease among oral contraceptive users to that among nonusers. The relative risk does not provide information on the actual clinical occurrence of a disease. Cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between oral contraceptive users and nonusers. The attributable risk does provide information about the actual occurrence of a disease in the population. For further information, the reader is referred to a text on epidemiological methods.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ef0859b4-809a-4a48-8171-8080bf143629"></a><a name="section-5.1"></a><p></p>
<h2>1. Thromboembolic Disorders and Other Vascular Problems</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f6837a2a-10d1-45dc-ab67-6a37ec8c2c35"></a><a name="section-5.1.1"></a><p></p>
<h3><span class="Bold">a. <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></h3>
<p class="First">An increased risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> has been attributed to oral contraceptive use. This risk is primarily in smokers or women with other underlying risk factors for <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">morbid obesity</span>, and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. The relative risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> for current oral contraceptive users has been estimated to be two to six. The risk is very low under the age of 30. Smoking in combination with oral contraceptive use has been shown to contribute substantially to the incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span> in women in their mid-thirties or older with smoking accounting for the majority of excess cases. Mortality rates associated with circulatory disease have been shown to increase substantially in smokers over the age of 35 and <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span> over the age of 40 (<a href="#id-1325559565">TABLE 2</a>) among women who use oral contraceptives.</p>
<p>TABLE : CIRCULATORY DISEASE MORTALITY RATES PER 100,000 WOMAN YEARS BY AGE, SMOKING STATUS AND ORAL CONTRACEPTIVE USE</p>
<div class="Figure">
<a name="id-1325559565"></a><img alt="TABLE 2 Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ee6be128-d494-4361-9a0d-341c0eee3587&amp;name=143d035e-f885-4ca9-a37c-b43e26c65aeb-03.jpg"><p class="MultiMediaCaption">Adapted from P.M. Layde and V. Beral, Lancet, 1:541-546, 1981. </p>
</div>
<p>Oral contraceptives may compound the effects of well-known risk factors, such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span>, age, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>. In particular, some progestogens are known to decrease HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and cause <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span>, while estrogens may create a state of <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinism</span>. Oral contraceptives have been shown to increase blood pressure among users (see section <a href="#ID_22f9a5f8-e7a1-45dc-aad0-cab26a9110ad">9</a> in <span class="Bold">WARNINGS</span>). Similar effects on risk factors have been associated with an increased risk of heart disease. Oral contraceptives must be used with caution in women with cardiovascular disease risk factor</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ba5e34f8-5ff7-4452-8463-516a7303c4dd"></a><a name="section-5.1.2"></a><p></p>
<h3><span class="Bold">b. <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span></span></h3>
<p class="First">An increased risk of thromboembolic and thrombotic disease associated with the use of oral contraceptives is well established. Case control studies have found the relative risk of users compared to nonusers to be 3 for the first episode of superficial <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, 4 to 11 for <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> or <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and 1.5 to 6 for women with predisposing conditions for venous thromboembolic disease. Cohort studies have shown the relative risk to be somewhat lower, about 3 for new cases and about 4.5 for new cases requiring hospitalization. The risk of thromboembolic disease due to oral contraceptives is not related to length of use and disappears after pill use is stopped.</p>
<p>A two- to four-fold increase in relative risk of postoperative thromboembolic complications has been reported with the use of oral contraceptives. The relative risk of <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> in women who have predisposing conditions is twice that of women without such medical conditions. If feasible, oral contraceptives should be discontinued at least four weeks prior to and for two weeks after elective surgery of a type associated with an increase in risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> and during and following prolonged immobilization. Since the immediate postpartum period is also associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, oral contraceptives should be started no earlier than four to six weeks after delivery in women who elect not to breast-feed, or a midtrimester pregnancy termination</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_08df9ca7-2d6f-4b39-a54a-ed5e4cc81465"></a><a name="section-5.1.3"></a><p></p>
<h3><span class="Bold">c. Cerebrovascular Diseases</span></h3>
<p class="First">Oral contraceptives have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span>), although, in general, the risk is greatest among older (&gt; 35 years), hypertensive women who also smoke. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> was found to be a risk factor for both users and nonusers, for both types of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, while smoking interacted to increase the risk for <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span>.</p>
<p>In a large study, the relative risk of <span class="product-label-link" type="condition" conceptid="4159140" conceptname="Thrombotic stroke">thrombotic strokes</span> has been shown to range from 3 for normotensive users to 14 for users with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. The relative risk of <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> is reported to be 1.2 for <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span> who used oral contraceptives, 2.6 for smokers who did not use oral contraceptives, 7.6 for smokers who used oral contraceptives, 1.8 for normotensive users, and 25.7 for users with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. The attributable risk is also greater in older women</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7c237041-2dac-4152-88ca-95b568335840"></a><a name="section-5.1.4"></a><p></p>
<h3><span class="Bold">d. Dose-Related Risk of Vascular Disease From Oral Contraceptives</span></h3>
<p class="First">A positive association has been observed between the amount of estrogen and progestogen in oral contraceptives and the risk of vascular disease. A decline in serum high-density lipoproteins (HDL) has been reported with many progestational agents. A decline in serum high-density lipoproteins has been associated with an increased incidence of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>. Because estrogens increase HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, the net effect of an oral contraceptive depends on a balance achieved between doses of estrogen and progestogen and the nature and absolute amount of progestogen used in the contraceptive. The amount of both hormones should be considered in the choice of an oral contraceptive.</p>
<p>Minimizing exposure to estrogen and progestogen is in keeping with good principles of therapeutics. For any particular estrogen/progestogen combination, the dosage regimen prescribed should be one which contains the least amount of estrogen and progestogen that is compatible with a low failure rate and the needs of the individual patient. New acceptors of oral contraceptive agents should be started on preparations containing less than 50 mcg of estrogen</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_72e9b359-db29-42e6-bd3b-4bca0bd6a550"></a><a name="section-5.1.5"></a><p></p>
<h3><span class="Bold">e. Persistence of Risk of Vascular Disease</span></h3>
<p class="First">There are two studies which have shown persistence of risk of vascular disease for ever-users of oral contraceptives. In a study in the United States, the risk of developing <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> after discontinuing oral contraceptives persists for at least 9 years for women 40 to 49 years who had used oral contraceptives for five or more years, but this increased risk was not demonstrated in other age groups. In another study in Great Britain, the risk of developing cerebrovascular disease persisted for at least 6 years after discontinuation of oral contraceptives, although excess risk was very small. However, both studies were performed with oral contraceptive formulations containing 50 micrograms or higher of estrogens</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_69a05f5c-43e1-4d2c-9293-3641695f5c7f"></a><a name="section-5.2"></a><p></p>
<h2>2. Estimates of Mortality From Oral Contraceptive Use</h2>
<p class="First">One study gathered data from a variety of sources which have estimated the mortality rate associated with different methods of contraception at different ages (<a href="#Table3">TABLE 3</a>). These estimates include the combined risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> associated with contraceptive methods plus the risk attributable to pregnancy in the event of method failure. Each method of contraception has its specific benefits and risks. The study concluded that with the exception of oral contraceptive users 35 and older who smoke and 40 and older who do not smoke, mortality associated with all methods of birth control is less than that associated with childbirth. The observation of a possible increase in risk of mortality with age for oral contraceptive users is based on data gathered in the 1970's – but not reported until 1983.  However, current clinical practice involves the use of lower estrogen dose formulations combined with careful restriction of oral contraceptive use to women who do not have the various risk factors listed in this labeling.</p>
<p>Because of these changes in practice and, also, because of some limited new data which suggest that the risk of cardiovascular disease with the use of oral contraceptives may now be less than previously observed, the Fertility and Maternal Health Drugs Advisory Committee was asked to review the topic in 1989. The Committee concluded that although cardiovascular disease risks may be increased with oral contraceptive use after age 40 in healthy nonsmoking women (even with the newer low-dose formulations), there are greater potential health risks associated with pregnancy in older women and with the alternative surgical and medical procedures which may be necessary if such women do not have access to effective and acceptable means of contraception.</p>
<p>Therefore, the Committee recommended that the benefits of oral contraceptive use by healthy nonsmoking women over 40 may outweigh the possible risks. Of course, older women, as all women who take oral contraceptives, should take the lowest possible dose formulation that is effective.</p>
<a name="_Ref384029518"></a><table>
<caption><span>TABLE 3: ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATHS</span> ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN, BY FERTILITY-CONTROL METHOD ACCORDING TO AGE</span></caption>
<col width="31%">
<col width="10%">
<col width="10%">
<col width="10%">
<col width="10%">
<col width="10%">
<col width="10%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are birth-related</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are method-relate</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Method of control and outcome</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">15 to 19</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20 to 24</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">25 to 29</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">30 to 34</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">35 to 39</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">40 to 44</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">No fertility-<br> control methods<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">7.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">9.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">14.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">25.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">28.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Oral contraceptives<br> non-smoker<a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">13.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">31.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Oral contraceptives<br> smoker<a href="#footnote-4" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">13.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">51.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">117.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">IUD<a href="#footnote-4" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Condom<a href="#footnote-3" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Diaphragm/spermicide<a href="#footnote-3" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Periodic abstinence<a href="#footnote-3" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.6</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" colspan="7" valign="top"><p class="First">Adapted from H.W. Ory, Family Planning Perspectives, <span class="Italics">15</span>:57-63, 1983.</p></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9c1dcd8a-c17e-4f63-bb0b-0bf370f87a79"></a><a name="section-5.3"></a><p></p>
<h2>3. Carcinoma of the Reproductive Organs</h2>
<p class="First">Numerous epidemiological studies have been performed on the incidence of breast, endometrial, ovarian, and cervical cancer in women using oral contraceptives. The overwhelming evidence in the literature suggests that use of oral contraceptives is not associated with an increase in the risk of developing breast cancer, regardless of the age and parity of first use or with most of the marketed brands and doses. The Cancer and Steroid Hormone (CASH) study also showed no latent effect on the risk of breast cancer for at least a decade following long-term use. A few studies have shown a slightly increased relative risk of developing breast cancer, although the methodology of these studies, which included differences in examination of users and nonusers and differences in age at start of use, has been questioned.</p>
<p>Some studies suggest that oral contraceptive use has been associated with an increase in the risk of <span class="product-label-link" type="condition" conceptid="198572" conceptname="Cervical intraepithelial neoplasia">cervical intraepithelial neoplasia</span> in some populations of women. However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.</p>
<p>In spite of many studies of the relationship between oral-contraceptive use and breast and cervical cancers, a cause-and-effect relationship has not been established</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_749fb45c-9a3e-4bb6-b607-d8d52d429f3a"></a><a name="section-5.4"></a><p></p>
<h2>4. <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Hepatic Neoplasia</span></h2>
<p class="First">Benign <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenomas</span> are associated with oral contraceptive use, although the incidence of benign tumors is rare in the United States. Indirect calculations have estimated the attributable risk to be in the range of 3.3 cases/100,000 for users, a risk that increases after four or more years of use. Rupture of rare, benign, <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenomas</span> may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> through intra-abdominal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</p>
<p>Studies from Britain have shown an increased risk of developing hepatocellular carcinoma in long-term (&gt; 8 years) oral contraceptive users. However, these cancers are extremely rare in the U.S., and the attributable risk (the excess incidence) of liver cancers in oral contraceptive users approaches less than one per million users.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6f6163e6-36db-43e1-8c07-a2d435064864"></a><a name="section-5.5"></a><p></p>
<h2>5. Ocular Lesions</h2>
<p class="First">There have been clinical case reports of retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> associated with the use of oral contraceptives. Oral contraceptives should be discontinued if there is unexplained partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>; onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span> or <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>; <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>; or retinal vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_994cdc75-8b81-4424-a41a-a085b7697812"></a><a name="section-5.6"></a><p></p>
<h2>6. Oral Contraceptive Use Before or During Early Pregnancy</h2>
<p class="First">Extensive epidemiological studies have revealed no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in women who have used oral contraceptives prior to pregnancy. Studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and limb-reduction defects are concerned, when taken inadvertently during early pregnancy. The administration of oral contraceptives to induce <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> should not be used as a test for pregnancy. Oral contraceptives should not be used during pregnancy to treat threatened or habitual abortion.</p>
<p>It is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out before continuing oral contraceptive use. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period. Oral contraceptive use should be discontinued if pregnancy is confirmed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a3095666-ae9a-49a6-83d1-d0625047657f"></a><a name="section-5.7"></a><p></p>
<h2>7. <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></h2>
<p class="First">Earlier studies have reported an increased lifetime relative risk of gallbladder surgery in users of oral contraceptives and estrogens. More recent studies, however, have shown that the relative risk of developing <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> among oral contraceptive users may be minimal. The recent findings of minimal risk may be related to the use of oral contraceptive formulations containing lower hormonal doses of estrogens and progestogens.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_08e65a69-d547-4372-be13-b1b5599cf6cb"></a><a name="section-5.8"></a><p></p>
<h2>8. Carbohydrate and Lipid Metabolic Effects</h2>
<p class="First">Oral contraceptives have been shown to cause <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span> in a significant percentage of users. Oral contraceptives containing greater than 75 micrograms of estrogens cause <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinism</span>, while lower doses of estrogen cause less <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span>. Progestogens increase insulin secretion and create <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span>, this effect varying with different progestational agents. However, in the nondiabetic woman, oral contraceptives appear to have no effect on fasting blood glucose. Because of these demonstrated effects, prediabetic and diabetic women should be carefully observed while taking oral contraceptives.</p>
<p>A small proportion of women will have persistent <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> while on the pill. As discussed earlier (see <span class="Bold">WARNINGS</span>, <span class="Italics"><a href="#ID_f6837a2a-10d1-45dc-ab67-6a37ec8c2c35">1a.</a></span> and <span class="Italics"><a href="#ID_7c237041-2dac-4152-88ca-95b568335840">1d.</a></span>), changes in serum triglycerides and lipoprotein levels have been reported in oral contraceptive users.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_22f9a5f8-e7a1-45dc-aad0-cab26a9110ad"></a><a name="section-5.9"></a><p></p>
<h2>9. Elevated Blood Pressure</h2>
<p class="First">An increase in blood pressure has been reported in women taking oral contraceptives, and this increase is more likely in older oral contraceptive users and with continued use. Data from the Royal College of General Practitioners and subsequent randomized trials have shown that the incidence of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> increases with increasing quantities of progestogens.</p>
<p>Women with a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>-related diseases, or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, should be encouraged to use another method of contraception. If women with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> elect to use oral contraceptives, they should be monitored closely, and if significant elevation of blood pressure occurs, oral contraceptives should be discontinued. For most women, elevated blood pressure will return to normal after stopping oral contraceptives, and there is no difference in the occurrence of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> among ever- and never-users.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_20b3e2b8-f485-44a0-8706-adfecc92ff19"></a><a name="section-5.10"></a><p></p>
<h2>10. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></h2>
<p class="First">The onset or exacerbation of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or development of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> with a new pattern that is recurrent, persistent, or severe requires discontinuation of oral contraceptives and evaluation of the cause.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f421559a-3374-4eb2-9640-d758f5a443ac"></a><a name="section-5.11"></a><p></p>
<h2>11. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Irregularities</h2>
<p class="First">Breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use. The type and dose of progestogen may be important. </p>
<p>Nonhormonal causes should be considered and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, as in the case of any abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. </p>
<p>If pathology has been excluded, time or a change to another formulation may solve the problem. In the event of <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, pregnancy should be ruled out. </p>
<p>Some women may encounter post-pill <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> or <span class="product-label-link" type="condition" conceptid="442274" conceptname="Oligomenorrhea">oligomenorrhea</span>, especially when such a condition was preexistent.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_96b8fe3d-182c-43be-be52-ff5fd7f28ddf"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><span class="Bold">Patients should be counseled that this product does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dfa74143-6519-4be2-9dba-028e706786d0"></a><a name="section-6.1"></a><p></p>
<h2>1. Physical Examination and Follow-up</h2>
<p class="First">A periodic history and physical examination is appropriate for all women, including women using oral contraceptives. The physical examination, however, may be deferred until after initiation of oral contraceptives if requested by the woman and judged appropriate by the clinician. The physical examination should include special reference to blood pressure, breasts, abdomen and pelvic organs, including cervical <span class="product-label-link" type="condition" conceptid="45771295" conceptname="Cytology">cytology</span>, and relevant laboratory tests. In case of undiagnosed, persistent, or recurrent abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>, appropriate measures should be conducted to rule out malignancy. Women with a strong family history of breast cancer or who have breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> should be monitored with particular care.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d1cb1f0d-6ad7-45fa-817b-a41aa91ad4a4"></a><a name="section-6.2"></a><p></p>
<h2>2. Lipid Disorders</h2>
<p class="First">Women who are being treated for <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span> should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span> more difficult. (See <span class="Bold">WARNINGS</span>, <span class="Italics"><a href="#ID_7c237041-2dac-4152-88ca-95b568335840">1d.</a></span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5c5e17f5-feda-42e7-b93d-d8d87dce91de"></a><a name="section-6.3"></a><p></p>
<h2>3. Liver Function</h2>
<p class="First">If <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> develops in any woman receiving such drugs, the medication should be discontinued. Steroid hormones may be poorly metabolized in patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_62653b23-bd24-4e7b-8184-ad86b2f9e618"></a><a name="section-6.4"></a><p></p>
<h2>4. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></h2>
<p class="First">Oral contraceptives may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_98139636-10f8-48d2-ae65-889f76cac93c"></a><a name="section-6.5"></a><p></p>
<h2>5. <span class="product-label-link" type="condition" conceptid="4305081" conceptname="Emotional problems">Emotional Disorders</span></h2>
<p class="First">Patients becoming significantly depressed while taking oral contraceptives should stop the medication and use an alternate method of contraception in an attempt to determine whether the symptom is drug related. Women with a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> should be carefully observed and the drug discontinued if <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> recurs to a serious degree.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7000a64e-72e8-4018-8e61-4cc0f458f080"></a><a name="section-6.6"></a><p></p>
<h2>6. Contact Lenses</h2>
<p class="First">Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_246410e2-1203-406e-94f7-3a0c8d0e5fa1"></a><a name="section-6.7"></a><p></p>
<h2>7. Drug Interactions</h2>
<p class="First">Reduced efficacy and increased incidence of breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and menstrual irregularities have been associated with concomitant use of rifampin. A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, and possibly with griseofulvin, ampicillin, and tetracyclines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_drug_lab_interaction_id_505c67e3-699e-4ef9-990c-1076903b3443"></a><a name="section-6.8"></a><p></p>
<h2>8. Interactions With Laboratory Tests</h2>
<p class="First">Certain endocrine- and liver-function tests and blood components may be affected by oral contraceptives:</p>
<dl>
<dt>1.</dt>
<dd>Increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> and factors VII, VIII, IX, and X; decreased antithrombin 3; increased norepinephrine-induced platelet aggregability.</dd>
<dt>2.</dt>
<dd>Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 by column or by radioimmunoassay. Free T3 resin uptake is decreased, reflecting the elevated TBG; free T4 concentration is unaltered.</dd>
<dt>3.</dt>
<dd>Other binding proteins may be elevated in serum.</dd>
<dt>4.</dt>
<dd>Sex-binding globulins are increased and result in elevated levels of total circulating sex steroids and corticoids; however, free or biologically active levels remain unchanged.</dd>
<dt>5.</dt>
<dd>Triglycerides may be increased.</dd>
<dt>6.</dt>
<dd>Glucose tolerance may be decreased.</dd>
<dt>7.</dt>
<dd>Serum folate levels may be depressed by oral contraceptive therapy. This may be of clinical significance if a woman becomes pregnant shortly after discontinuing oral contraceptives.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_6545822d-2407-456c-9f8c-e42e7f497c73"></a><a name="section-6.9"></a><p></p>
<h2>9. Carcinogenesis</h2>
<p class="First">See <span class="Bold"><a href="#i4i_warnings_id_e7ecba4d-3c65-474f-b330-3841c25c9719">WARNINGS</a></span> section.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_2a223b3b-3829-4861-a889-162d8435dfa9"></a><a name="section-6.10"></a><p></p>
<h2>10. Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_163ad49a-b41b-4453-9918-39f520303b35"></a><a name="section-6.10.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects</span></h3>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4c0119b6-e1a3-410f-b810-f724ebece02e"></a><a name="section-6.10.2"></a><p></p>
<h3><span class="Underline">Pregnancy Category X</span></h3>
<p class="First">See <span class="Bold"><a href="#i4i_contraindications_id_d460b877-5558-4400-976b-2778fa9735a0">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#i4i_warnings_id_e7ecba4d-3c65-474f-b330-3841c25c9719">WARNINGS</a></span> sections</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_4a36c992-4b1a-43c4-9ba3-66ba13d7c25b"></a><a name="section-6.11"></a><p></p>
<h2>11. Nursing Mothers</h2>
<p class="First">Small amounts of oral contraceptive steroids have been identified in the milk of nursing mothers, and a few adverse effects on the child have been reported, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>. In addition, oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use oral contraceptives but to use other forms of contraception until she has completely weaned her child.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_5d0fc0ef-2242-4714-b407-7d1aba8b57a4"></a><a name="section-6.12"></a><p></p>
<h2>12. Pediatric Use</h2>
<p class="First">Safety and efficacy of norgestrel and ethinyl estradiol tablets have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and users 16 and older. Use of this product before <span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span> is not indicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_49a56f5f-b98e-4425-b296-2ec140bd8334"></a><a name="section-7"></a><p></p>
<h1>INFORMATION FOR THE PATIENT</h1>
<p class="First">See Patient Labeling printed below.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_b6367e88-7c15-4554-b425-c3c61e730478"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see <span class="Bold"><a href="#i4i_warnings_id_e7ecba4d-3c65-474f-b330-3841c25c9719">WARNINGS</a></span> section):</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span></dd>
<dt>•</dt>
<dd>Arterial <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="441874" conceptname="Cerebral thrombosis">Cerebral thrombosis</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">Hepatic adenomas</span> or benign <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span></dd>
</dl>
<p>There is evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed: </p>
<dl>
<dt>•</dt>
<dd>Mesenteric <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> </dd>
<dt>•</dt>
<dd>Retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span></dd>
</dl>
<p>The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug related:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal symptoms</span> (such as <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span> and <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>)</dd>
<dt>•</dt>
<dd>Breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></dd>
<dt>•</dt>
<dd>Spotting</dd>
<dt>•</dt>
<dd>Change in menstrual flow</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span></dd>
<dt>•</dt>
<dd>Temporary <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> after discontinuation of treatment</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Melasma</span> which may persist</dd>
<dt>•</dt>
<dd>Breast changes: <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, enlargement, secretion</dd>
<dt>•</dt>
<dd>Change in weight (increase or decrease)</dd>
<dt>•</dt>
<dd>Change in cervical erosion and secretion</dd>
<dt>•</dt>
<dd>Diminution in lactation when given immediately postpartum</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (allergic)</dd>
<dt>•</dt>
<dd>Mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></dd>
<dt>•</dt>
<dd>Reduced tolerance to carbohydrates</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">Vaginal candidiasis</span></dd>
<dt>•</dt>
<dd>Change in corneal curvature (steepening)</dd>
<dt>•</dt>
<dd>Intolerance to contact lenses</dd>
</dl>
<p>The following adverse reactions have been reported in users of oral contraceptives, and the association has been neither confirmed nor refuted:</p>
<dl>
<dt>•</dt>
<dd>Congenital anomalies</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="439081" conceptname="Premenstrual tension syndrome">Premenstrual syndrome</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">Optic neuritis</span></dd>
<dt>•</dt>
<dd>Changes in appetite</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span>-like syndrome</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span></dd>
<dt>•</dt>
<dd>Loss of scalp hair</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">Erythema nodosum</span></dd>
<dt>•</dt>
<dd>Hemorrhagic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">Porphyria</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic uremic syndrome</span></dd>
<dt>•</dt>
<dd>Budd-Chiari syndrome</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></dd>
<dt>•</dt>
<dd>Changes in libido</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span></dd>
<dt>•</dt>
<dd>Sickle-cell disease</dd>
<dt>•</dt>
<dd>Cerebral-vascular disease with <span class="product-label-link" type="condition" conceptid="4252872" conceptname="Mitral valve prolapse">mitral valve prolapse</span></dd>
<dt>•</dt>
<dd>Lupus-like syndromes</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_838931c4-1e6d-4f51-a27c-bc65d5f9efeb"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> may occur in females.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e3967cd0-1b87-417c-bf51-9443f3b68fab"></a><a name="section-10"></a><p></p>
<h1>NONCONTRACEPTIVE HEALTH BENEFITS</h1>
<p class="First">The following noncontraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral contraceptive formulations containing doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of mestranol.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c71295bc-cfd4-4d13-adbb-9330b74cad2d"></a><a name="section-10.1"></a><p></p>
<h2>Effects on Menses</h2>
<dl>
<dt>•</dt>
<dd>Increased menstrual cycle regularity</dd>
<dt>•</dt>
<dd>Decreased blood loss and decreased incidence of iron-<span class="product-label-link" type="condition" conceptid="4280354" conceptname="Nutritional anemia">deficiency anemia</span></dd>
<dt>•</dt>
<dd>Decreased incidence of <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_539cc40f-b8d3-4990-9b22-57e8efb470bc"></a><a name="section-10.2"></a><p></p>
<h2>Effects Related to Inhibition of Ovulation</h2>
<dl>
<dt>•</dt>
<dd> Decreased incidence of functional <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cysts</span></dd>
<dt>•</dt>
<dd>Decreased incidence of ectopic pregnancies</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0b245493-d6a3-4809-a906-47dc4ce2bebd"></a><a name="section-10.3"></a><p></p>
<h2>Effects From Long-term Use</h2>
<dl>
<dt>•</dt>
<dd>Decreased incidence of fibroadenomas and fibrocystic disease of the breast</dd>
<dt>•</dt>
<dd>Decreased incidence of acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span></dd>
<dt>•</dt>
<dd>Decreased incidence of endometrial cancer</dd>
<dt>•</dt>
<dd>Decreased incidence of ovarian cancer</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_9a60f92c-f49f-4c9d-9738-fd30eb06c091"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">To achieve maximum contraceptive effectiveness, Cryselle<span class="Sup">®</span> must be taken exactly as directed and at intervals not exceeding 24 hours. The dosage of Cryselle<span class="Sup">®</span> is one white tablet daily for 21 consecutive days, followed by one light-green inert tablet daily for 7 consecutive days, according to prescribed schedule. It is recommended that tablets be taken at the same time each day, preferably after the evening meal or at bedtime.</p>
<p>During the first cycle of medication, the patient is instructed to begin taking Cryselle<span class="Sup">®</span> on the first Sunday after the onset of menstruation. If menstruation begins on a Sunday, the first tablet (white) is taken that day. One white tablet should be taken daily for 21 consecutive days followed by one light-green inert tablet daily for 7 consecutive days.</p>
<p><span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">Withdrawal bleeding</span> should usually occur within three days following discontinuation of white tablets. During the first cycle, contraceptive reliance should not be placed on Cryselle<span class="Sup">®</span> until a white tablet has been taken daily for 7 consecutive days. The possibility of ovulation and conception prior to initiation of medication should be considered.</p>
<p>The patient begins her next and all subsequent 28 day courses of tablets on the same day of the week (Sunday) on which she began her first course, following the same schedule: 21 days on white tablets – 7 days on light-green inert tablets. If in any cycle the patient starts tablets later than the proper day, she should protect herself by using another method of birth control until she has taken a white tablet daily for 7 consecutive days.</p>
<p>If spotting or breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs, the patient is instructed to continue on the same regimen. This type of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is usually transient and without significance; however, if the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is persistent or prolonged, the patient is advised to consult her physician.</p>
<p>Although the occurrence of pregnancy is highly unlikely if Cryselle<span class="Sup">®</span> is taken according to directions, if <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> does not occur, the possibility of pregnancy must be considered. If the patient has not adhered to the prescribed schedule (missed one or more tablets or started taking them on a day later than she should have), the probability of pregnancy should be considered at the time of the first missed period and appropriate diagnostic measures taken before the medication is resumed. If the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out before continuing the contraceptive regimen.</p>
<p>For additional patient instructions regarding missed pills, see the "<span class="Bold">WHAT TO DO IF YOU MISS PILLS</span>" section in the <span class="Bold">DETAILED PATIENT LABELING </span>below.</p>
<p>Any time the patient misses two or more white tablets, she should also use another method of contraception until she has taken a white tablet daily for seven consecutive days. If the patient misses one or more light-green tablets, she is still protected against pregnancy <span class="Bold">provided </span>she begins taking white tablets again on the proper day. If breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs following missed white tablets, it will usually be transient and of no consequence. While there is little likelihood of ovulation occurring if only one or two tablets are missed, the possibility of ovulation increases with each successive day that scheduled white tablets are missed.</p>
<p>In the nonlactating mother, Cryselle<span class="Sup">®</span> may be initiated postpartum, for contraception. When the tablets are administered in the postpartum period, the increased risk of thromboembolic disease associated with the postpartum period must be considered (see <span class="Bold"><a href="#i4i_contraindications_id_d460b877-5558-4400-976b-2778fa9735a0">CONTRAINDICATIONS</a></span>, <span class="Bold"><a href="#i4i_warnings_id_e7ecba4d-3c65-474f-b330-3841c25c9719">WARNINGS</a></span>, and <span class="Bold"><a href="#i4i_precautions_id_96b8fe3d-182c-43be-be52-ff5fd7f28ddf">PRECAUTIONS</a></span> concerning thromboembolic disease). It is to be noted that early resumption of ovulation may occur if Parlodel<span class="Sup">®</span> (bromocriptine mesylate) has been used for the prevention of lactation.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_66f84f54-ce2a-43ba-8248-250b84ab675f"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Cryselle<span class="Sup">®</span> (norgestrel and ethinyl estradiol tablets USP), 0.3 mg/0.03 mg are available in packages of 6 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card dispensers, each containing 28 tablets as follows: 21 active, white, round, film-coated, biconvex tablets debossed with dp on one side and 543 on the other side and 7 inert, round, light-green colored, uncoated tablets debossed dp and 331.</p>
<p>Store at 20º to 25°C (68° to 77º F) [See USP Controlled Room Temperature].</p>
<p>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</p>
<p><span class="Bold">REFERENCES AVAILABLE UPON REQUEST</span></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_b81a10ef-682d-4271-b639-71fb96161803"></a><a name="section-13"></a><p></p>
<h1>BRIEF SUMMARY PATIENT PACKAGE INSERT</h1>
<p class="First"><span class="Bold">This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</span></p>
<p>Oral contraceptives, also known as "birth control pills" or "the pill," are taken to prevent pregnancy, and when taken correctly, have a failure rate of less than 1% per year when used without missing any pills. The typical failure rate of large numbers of pill users is less than 3% per year when women who miss pills are included. For most women oral contraceptives are also free of serious or unpleasant side effects. However, forgetting to take pills considerably increases the chances of pregnancy.</p>
<p>For the majority of women, oral contraceptives can be taken safely. But there are some women who are at high risk of developing certain serious diseases that can be life-threatening or may cause temporary or permanent <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The risks associated with taking oral contraceptives increase significantly if you:</p>
<dl>
<dt>•</dt>
<dd>smoke.</dd>
<dt>•</dt>
<dd>have high blood pressure, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>.</dd>
<dt>•</dt>
<dd>have or have had <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">clotting disorders</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, cancer of the breast or sex organs, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, or malignant or benign <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span>.</dd>
</dl>
<p>You should not take the pill if you suspect you are pregnant or have unexplained <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>.</p>
<div class="Warning">
<a name="i4i_table_id_d55f3a0b-6784-4658-b1aa-033567fe2854"></a><a name="section-13.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should not smoke.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a21618d9-d517-46e8-9290-d94944a79f76"></a><a name="section-13.1"></a><p></p>
<p class="First">Most side effects of the pill are not serious. The most common such effects are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> between menstrual periods, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, and difficulty wearing contact lenses. </p>
<p>These side effects, especially <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, may subside within the first three months of use. </p>
<p>The serious side effects of the pill occur very infrequently, especially if you are in good health and do not smoke. However, you should know that the following medical conditions have been associated with or made worse by the pill:</p>
<dl>
<dt>1.</dt>
<dd>Blood clots in the legs (<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>), lungs (<span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>), stoppage or rupture of a blood vessel in the brain (<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>), blockage of blood vessels in the heart (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> and <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>) or other organs of the body. As mentioned above, smoking increases the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and subsequent serious medical consequences.</dd>
<dt>2.</dt>
<dd><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumors</span>, which may rupture and cause severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. A possible but not definite association has been found with the pill and liver cancer. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer.</dd>
<dt>3.</dt>
<dd>High blood pressure, although blood pressure usually returns to normal when the pill is stopped.</dd>
</dl>
<p>The symptoms associated with these serious side effects are discussed in the detailed leaflet given to you with your supply of pills. Notify your doctor or healthcare provider if you notice any unusual physical disturbances while taking the pill. In addition, drugs such as rifampin, as well as some anticonvulsants and some antibiotics, may decrease oral contraceptive effectiveness. </p>
<p>Studies to date of women taking the pill have not shown an increase in the incidence of cancer of the breast or cervix. There is, however, insufficient evidence to rule out the possibility that pills may cause such cancers. </p>
<p>Taking the pill provides some important noncontraceptive benefits. These include less painful menstruation, less menstrual blood loss and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, fewer <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">pelvic infections</span>, and fewer cancers of the ovary and the lining of the uterus.</p>
<p>Be sure to discuss any medical condition you may have with your healthcare provider. Your healthcare provider will take a medical and family history before prescribing oral contraceptives and will examine you. The physical examination may be delayed to another time if you request it and the healthcare provider believes that it is appropriate to postpone it. You should be reexamined at least once a year while taking oral contraceptives. The detailed patient information leaflet gives you further information which you should read and discuss with your healthcare provider. </p>
<p><span class="Bold">DETAILED PATIENT LABELING</span></p>
<p><span class="Bold">This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</span></p>
<p><span class="Bold">INTRODUCTION</span></p>
<p>Any woman who considers using oral contraceptives (the birth control pill or the pill) should understand the benefits and risks of using this form of birth control. This leaflet will give you much of the information you will need to make this decision and will also help you determine if you are at risk of developing any of the serious side effects of the pill. It will tell you how to use the pill properly so that it will be as effective as possible. However, this leaflet is not a replacement for a careful discussion between you and your healthcare provider. You should discuss the information provided in this leaflet with him or her, both when you first start taking the pill and during your revisits. You should also follow your healthcare provider's advice with regard to regular check-ups while you are on the pill.</p>
<p><span class="Bold">EFFECTIVENESS OF ORAL CONTRACEPTIVES</span></p>
<p>Oral contraceptives or "birth control pills" or "the pill" are used to prevent pregnancy and are more effective than other nonsurgical methods of birth control. When they are taken correctly, the chance of becoming pregnant is less than 1% when used perfectly, without missing any pills. Typical failure rates are less than 3% per year. The chance of becoming pregnant increases with each missed pill during the menstrual cycle. </p>
<p>In comparison, typical failure rates for other nonsurgical methods of birth control during the first year of use are as follows:</p>
<table>
<caption><span>TABLE: PERCENTAGE OF WOMEN EXPERIENCING AN <span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">UNINTENDED PREGNANCY</span> DURING THE FIRST YEAR OF USE OF A CONTRACEPTIVE METHOD </span></caption>
<col width="70%">
<col width="15%">
<col width="15%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>NA - not available</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>Depending on method (calendar, ovulation, symptothermal, post-ovulation)</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Method</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Perfect Use</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Typical Use</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Levonorgestrel implants</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.05</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.05</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Male sterilization</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.15</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Female sterilization</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Depo-Provera<span class="Sup">®</span> (injectable progestogen)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Oral contraceptives</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     Combined</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">NA<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     Progestin only</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">NA<a href="#footnote-5" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">IUD</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     Progesterone</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     Copper T 380A</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Condom (male) without spermicide</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">14</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     (female) without spermicide</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">21</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Cervical cap</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     Never given birth</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     Given birth</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">26</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">40</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Vaginal sponge</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     Never given birth</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     Given birth</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">40</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Diaphragm with spermicidal cream or jelly</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Spermicides alone (foam, creams, jellies, and vaginal suppositories)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">26</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Periodic abstinence (all methods)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 to 9<a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">25</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Withdrawal</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">19</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">No contraception (planned pregnancy)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">85</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">85</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First">Adapted from Hatcher RA et al, <span class="Italics">Contraceptive Technology: 17<span class="Sup">th</span> Revised Edition</span>. NY, NY: Ardent Media, Inc., 1998.</p></td></tr>
</tbody>
</table>
<p><span class="Bold">WHO SHOULD NOT TAKE ORAL CONTRACEPTIVES</span></p>
<table>
<col width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should not smoke.</span></p></td></tr></tbody>
</table>
<p>Some women should not use the pill. For example, you should not take the pill if you are pregnant or think you may be pregnant. You should also not use the pill if you have had any of the following conditions:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></dd>
<dt>•</dt>
<dd>Blood clots in the legs (<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>), lungs (<span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>), or eyes</dd>
<dt>•</dt>
<dd>Blood clots in the deep veins of your legs</dd>
<dt>•</dt>
<dd>Known or suspected breast cancer or cancer of the lining of the uterus, cervix, or vagina</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumor</span> (benign or cancerous)</dd>
</dl>
<p>Or, if you have any of the following:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> (<span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>)</dd>
<dt>•</dt>
<dd>Unexplained <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> (until a diagnosis is reached by your doctor)</dd>
<dt>•</dt>
<dd>Yellowing of the whites of the eyes or of the skin (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>) during pregnancy or during previous use of the pill</dd>
<dt>•</dt>
<dd>Known or suspected pregnancy</dd>
</dl>
<p>Tell your healthcare provider if you have ever had any of these conditions. Your healthcare provider can recommend another method of birth control.</p>
<p><span class="Bold">OTHER CONSIDERATIONS BEFORE TAKING ORAL CONTRACEPTIVES</span></p>
<p>Tell your healthcare provider if you or any family member has ever had:</p>
<dl>
<dt>•</dt>
<dd>Breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>, fibrocystic disease of the breast, an abnormal breast X ray or mammogram</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></dd>
<dt>•</dt>
<dd>Elevated <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or triglycerides</dd>
<dt>•</dt>
<dd>High blood pressure</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> or other <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> or <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span></dd>
<dt>•</dt>
<dd>Mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></dd>
<dt>•</dt>
<dd>Gallbladder, heart, or kidney disease</dd>
<dt>•</dt>
<dd>History of scanty or irregular menstrual periods</dd>
</dl>
<p>Women with any of these conditions should be checked often by their healthcare provider if they choose to use oral contraceptives. Also, be sure to inform your doctor or healthcare provider if you smoke or are on any medications. </p>
<p><span class="Bold">RISKS OF TAKING ORAL CONTRACEPTIVES</span></p>
<dl>
<dt>1.</dt>
<dd>
<span class="Bold">Risk of Developing Blood Clots</span><br>Blood clots and blockage of blood vessels are the most serious side effects of taking oral contraceptives and can be fatal. In particular, a clot in the legs can cause <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> and a clot that travels to the lungs can cause a sudden blocking of the vessel carrying blood to the lungs. Rarely, clots occur in the blood vessels of the eye and may cause <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>, or impaired vision. <br>If you take oral contraceptives and need elective surgery, need to stay in bed for a prolonged illness, or have recently delivered a baby, you may be at risk of developing blood clots. You should consult your doctor about stopping oral contraceptives three to four weeks before surgery and not taking oral contraceptives for two weeks after surgery or during bed rest. You should also not take oral contraceptives soon after delivery of a baby or a midtrimester pregnancy termination. It is advised to wait for at least four weeks after delivery if you are not breastfeeding. If you are breastfeeding, you should wait until you have weaned your child before using the pill. (See also the section on breastfeeding in <span class="Bold">GENERAL PRECAUTIONS</span>.)</dd>
<dt>2.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart Attacks</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Strokes</span></span><br>Oral contraceptives may increase the tendency to develop <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> (stoppage or rupture of blood vessels in the brain) and <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> (blockage of blood vessels in the heart). Any of these conditions can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or serious <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. <br>Smoking greatly increases the possibility of suffering <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>. Furthermore, smoking and the use of oral contraceptives greatly increase the chances of developing and dying of heart disease.</dd>
<dt>3.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></span><br>Oral contraceptive users probably have a greater risk than nonusers of having <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>, although this risk may be related to pills containing high doses of estrogens.</dd>
<dt>4.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver Tumors</span></span><br>In rare cases, oral contraceptives can cause benign but dangerous <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span>. These benign <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span> can rupture and cause fatal internal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. In addition, a possible but not definite association has been found with the pill and liver cancers in two studies in which a few women who developed these very rare cancers were found to have used oral contraceptives for long periods. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer.</dd>
<dt>5.</dt>
<dd>
<span class="Bold">Cancer of the Reproductive Organs</span><br>There is, at present, no confirmed evidence that oral contraceptives increase the risk of cancer of the reproductive organs in human studies. Several studies have found no overall increase in the risk of developing breast cancer. However, women who use oral contraceptives and have a strong family history of breast cancer or who have breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> or abnormal mammograms should be closely followed by their doctors. <br>Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives.<br>
</dd>
</dl>
<p><span class="Bold">ESTIMATED RISK OF <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span> FROM A BIRTH CONTROL METHOD OR PREGNANCY</span></p>
<p>All methods of birth control and pregnancy are associated with a risk of developing certain diseases which may lead to <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. An estimate of the number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> associated with different methods of birth control and pregnancy has been calculated and is shown in the following table. </p>
<table>
<caption><span>ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATHS</span> ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN, BY FERTILITY-CONTROL METHOD ACCORDING TO AGE </span></caption>
<col width="31%">
<col width="10%">
<col width="10%">
<col width="10%">
<col width="10%">
<col width="10%">
<col width="10%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are birth-related</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are method-related</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Method of control and outcome</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">15 to 19</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20 to 24</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">25 to 29</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">30 to 34</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">35 to 39</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">40 to 44</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">No fertility-<br> control methods<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">7.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">9.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">14.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">25.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">28.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Oral contraceptives<br> non-smoker<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">13.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">31.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Oral contraceptives<br> smoker<a href="#footnote-8" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">13.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">51.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">117.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">IUD<a href="#footnote-8" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Condom<a href="#footnote-7" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Diaphragm/spermicide<a href="#footnote-7" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.8</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Periodic abstinence<a href="#footnote-7" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.6</p></td>
</tr>
</tbody>
</table>
<p>In the above table, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any birth control method is less than the risk of childbirth, except for oral contraceptive users over the age of 35 who smoke and pill users over the age of 40 even if they do not smoke. It can be seen in the table that for women aged 15 to 39, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was highest with pregnancy (7 to 26 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> per 100,000 women, depending on age). Among pill users who do not smoke, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was always lower than that associated with pregnancy for any age group, except for those women over the age of 40, when the risk increases to 32 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> per 100,000 women, compared to 28 associated with pregnancy at that age. However, for pill users who smoke and are over the age of 35, the estimated number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> exceeds those for other methods of birth control. If a woman is over the age of 40 and smokes, her estimated risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> is four times higher (117/100,000 women) than the estimated risk associated with pregnancy (28/100,000 women) in that age group. </p>
<p>The suggestion that women over 40 who don't smoke should not take oral contraceptives is based on information from older high-dose pills and on less-selective use of pills than is practiced today. An Advisory Committee of the FDA discussed this issue in 1989 and recommended that the benefits of oral contraceptive use by healthy, nonsmoking women over 40 years of age may outweigh the possible risks. However, all women, especially older women, are cautioned to use the lowest-dose pill that is effective.</p>
<p><span class="Bold">WARNING SIGNALS</span></p>
<p>If any of these adverse effects occur while you are taking oral contraceptives, call your doctor immediately:</p>
<dl>
<dt>•</dt>
<dd>Sharp <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> of blood, or sudden <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> (indicating a possible clot in the lung)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> in the calf (indicating a possible clot in the leg)</dd>
<dt>•</dt>
<dd>Crushing <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or heaviness in the chest (indicating a possible <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>)</dd>
<dt>•</dt>
<dd>Sudden severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, disturbances of vision or speech, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in an arm or leg (indicating a possible <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>)</dd>
<dt>•</dt>
<dd>Sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> (indicating a possible clot in the eye)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span> (indicating possible breast cancer or fibrocystic disease of the breast; ask your doctor or healthcare provider to show you how to examine your breasts)</dd>
<dt>•</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> in the stomach area (indicating a possibly ruptured <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumor</span>)</dd>
<dt>•</dt>
<dd>Difficulty in sleeping, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, lack of energy, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, or change in mood (possibly indicating severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> or a yellowing of the skin or eyeballs, accompanied frequently by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, loss of appetite, dark-colored urine, or light-colored bowel movements (indicating possible liver problems)</dd>
</dl>
<p><span class="Bold">SIDE EFFECTS OF ORAL CONTRACEPTIVES</span></p>
<dl>
<dt>1.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></span><br>Irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting may occur while you are taking the pills. Irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may vary from slight staining between menstrual periods to breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> which is a flow much like a regular period. Irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs most often during the first few months of oral contraceptive use, but may also occur after you have been taking the pill for some time. Such <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may be temporary and usually does not indicate any serious problems. It is important to continue taking your pills on schedule. If the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs in more than one cycle or lasts for more than a few days, talk to your doctor or healthcare provider.</dd>
<dt>2.</dt>
<dd>
<span class="Bold">Contact Lenses</span><br>If you wear contact lenses and notice a change in vision or an inability to wear your lenses, contact your doctor or healthcare provider.</dd>
<dt>3.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></span><br>Oral contraceptives may cause <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>) with <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the fingers or ankles and may raise your blood pressure. If you experience <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, contact your doctor or healthcare provider.</dd>
<dt>4.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Melasma</span></span><br>A spotty darkening of the skin is possible, particularly of the face.</dd>
<dt>5.</dt>
<dd>
<span class="Bold">Other Side Effects</span><br>Other side effects may include change in appetite, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, loss of scalp hair, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infections</span>.</dd>
</dl>
<p>If any of these side effects bother you, call your doctor or healthcare provider.</p>
<p><span class="Bold">GENERAL PRECAUTIONS</span></p>
<p><span class="Bold">1. Missed Periods and Use of Oral Contraceptives Before or During Early Pregnancy</span><br>There may be times when you may not menstruate regularly after you have completed taking a cycle of pills. If you have taken your pills regularly and miss one menstrual period, continue taking your pills for the next cycle but be sure to inform your healthcare provider before doing so. If you have not taken the pills daily as instructed and missed a menstrual period, or if you missed two consecutive menstrual periods, you may be pregnant. Check with your healthcare provider immediately to determine whether you are pregnant. Do not continue to take oral contraceptives until you are sure you are not pregnant, but continue to use another method of contraception.</p>
<p><br>There is no conclusive evidence that oral contraceptive use is associated with an increase in <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> when taken inadvertently during early pregnancy. Previously, a few studies had reported that oral contraceptives might be associated with <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, but these studies have not been confirmed. Nevertheless, oral contraceptives or any other drugs should not be used during pregnancy unless clearly necessary and prescribed by your doctor. You should check with your doctor about risks to your unborn child of any medication taken during pregnancy.</p>
<p><span class="Bold">2. While Breastfeeding</span><br>If you are breastfeeding, consult your doctor before starting oral contraceptives. Some of the drug will be passed on to the child in the milk. A few adverse effects on the child have been reported, including yellowing of the skin (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>) and <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>. In addition, oral contraceptives may decrease the amount and quality of your milk. If possible, do not use oral contraceptives while breastfeeding. You should use another method of contraception since breastfeeding provides only partial protection from becoming pregnant, and this partial protection decreases significantly as you breastfeed for longer periods of time. <br>You should consider starting oral contraceptives only after you have weaned your child completely.</p>
<p><span class="Bold">3. Laboratory Tests</span><br>If you are scheduled for any laboratory tests, tell your doctor you are taking birth control pills. Certain blood tests may be affected by birth control pills.</p>
<p><span class="Bold">4. Drug Interactions</span><br>Certain drugs may interact with birth control pills to make them less effective in preventing pregnancy or cause an increase in breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Such drugs include rifampin, drugs used for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> such as barbiturates (for example, phenobarbital) and phenytoin (Dilantin<span class="Sup">®</span> is one brand of this drug), phenylbutazone (Butazolidin<span class="Sup">®</span> is one brand), and possibly certain antibiotics. You may need to use an additional method of contraception during any cycle in which you take drugs that can make oral contraceptives less effective.</p>
<p><span class="Bold">HOW TO TAKE THE PILL</span></p>
<p>This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span> such as chlamydia, <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>, <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B, and <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>.</p>
<p><span class="Bold">IMPORTANT POINTS TO REMEMBER</span></p>
<p><span class="Italics">BEFORE</span> YOU START TAKING YOUR PILLS:</p>
<dl>
<dt>1.</dt>
<dd>BE SURE TO READ THESE DIRECTIONS: <br>Before you start taking your pills. <br>Anytime you are not sure what to do.</dd>
<dt>2.</dt>
<dd>THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. <br>If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant.</dd>
<dt>3.</dt>
<dd>MANY WOMEN HAVE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST 1 TO 3 PACKS OF PILLS. <br>If you feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn't go away, check with your doctor or clinic.</dd>
<dt>4.</dt>
<dd>MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, even when you make up these missed pills. <br>On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach.</dd>
<dt>5.</dt>
<dd>IF YOU HAVE <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">VOMITING</span> OR <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span>, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your pills may not work as well. <br>Use a back-up method (such as condoms or foam) until you check with your doctor or clinic.</dd>
<dt>6.</dt>
<dd>IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control.</dd>
<dt>7.</dt>
<dd>IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or clinic.</dd>
</dl>
<p><span class="Bold"><span class="Italics">BEFORE</span> YOU START TAKING YOUR PILLS</span></p>
<dl>
<dt>1.</dt>
<dd>DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL. It is important to take it at about the same time every day.</dd>
<dt>2.</dt>
<dd>LOOK AT YOUR PILL PACK TO SEE IF IT HAS 28 PILLS:<br>The <span class="Italics"><span class="Underline">28 pill pack</span></span> has 21 "active" [white] pills (with hormones) to take for 3 weeks, followed by 1 week of "reminder" [light-green colored] pills (without hormones).</dd>
<dt>3.</dt>
<dd>ALSO FIND:<br>1) where on the pack to start taking the pills, <br>2) in what order to take the pills (follow the arrows) and<br>3) the week numbers printed on the pack.<br><br>Example Only:</dd>
</dl>
<div class="Figure">
<a name="id-1069474918"></a><img alt="28 Pill Pack <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ee6be128-d494-4361-9a0d-341c0eee3587&amp;name=143d035e-f885-4ca9-a37c-b43e26c65aeb-04.jpg">
</div>
<p>4. BE SURE YOU HAVE READY AT ALL TIMES:<br>ANOTHER KIND OF BIRTH CONTROL (such as condoms or foam) to use as a back-up                              method in case you miss pills.<br>AN EXTRA, FULL PILL PACK.</p>
<p><span class="Bold">WHEN TO START THE <span class="Italics">FIRST</span> PACK OF PILLS</span><br>You have a choice of which day to start taking your first pack of pills. (See DAY 1 START or SUNDAY START directions below.) Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember.</p>
<p><span class="Bold">DAY 1 START:</span></p>
<dl>
<dt>1.</dt>
<dd>Pick the day label strip that starts with the first day of your period (this is the day you start <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting, even if it is almost midnight when the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> begins.)</dd>
<dt>2.</dt>
<dd>Place this day label strip on the cycle tablet dispenser over the area that has the days of the week (starting with Sunday) printed on the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card.</dd>
</dl>
<div class="Figure">
<a name="id-1069474917"></a><img alt="Pick Correct Day Label <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ee6be128-d494-4361-9a0d-341c0eee3587&amp;name=143d035e-f885-4ca9-a37c-b43e26c65aeb-05.jpg">
</div>
<p>Note: If the first day of your period is a Sunday, you can skip steps #1 and #2.</p>
<p>3.  Take the first "active" [white] pill of the first pack during the <span class="Italics">first 24 hours of your period</span>.</p>
<p>4.  You will not need to use a back-up method of birth control, since you are starting the pill at   the beginning of your period.</p>
<p><span class="Bold">SUNDAY START:</span></p>
<dl>
<dt>1.</dt>
<dd>Take the first "active" [white] pill of the first pack on the <span class="Italics">Sunday after your period starts</span>, even if you are still <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. If your period begins on Sunday, start the pack that same day.</dd>
<dt>2.</dt>
<dd>
<span class="Italics">Use another method of birth control</span> as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms or foam are good back-up methods of birth control.</dd>
</dl>
<p><span class="Bold">WHAT TO DO DURING THE MONTH</span></p>
<dl>
<dt>1.</dt>
<dd>
<span class="Bold">TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY.</span><br>Do not skip pills even if you are spotting or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> between monthly periods or feel sick to your stomach (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>).<br>Do not skip pills even if you do not have sex very often.</dd>
<dt>2.</dt>
<dd>
<span class="Bold">WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS:</span><br><span class="Italics">21 pills:</span> Wait 7 days to start the next pack. You will probably have your period during that week. Be sure that no more than 7 days pass between 21 day packs.<br><span class="Italics">28 pills:</span> Start the next pack on the day after your last "reminder" pill. Do not wait any days between packs.</dd>
</dl>
<p><span class="Bold">WHAT TO DO IF YOU MISS PILLS</span></p>
<p>If you <span class="Bold">MISS 1</span> [white] "active" pill:</p>
<dl>
<dt>1.</dt>
<dd>Take it as soon as you remember: Take the next pill at your regular time. This means you take 2 pills in 1 day.</dd>
<dt>2.</dt>
<dd>You do not need to use a back-up birth control method if you have sex.</dd>
</dl>
<p>If you <span class="Bold">MISS 2</span> [white] "active" pills in a row in <span class="Bold">WEEK 1 OR WEEK 2</span> of your pack:</p>
<dl>
<dt>1.</dt>
<dd>Take 2 pills on the day you remember and 2 pills the next day.</dd>
<dt>2.</dt>
<dd>Then take 1 pill a day until you finish the pack.</dd>
<dt>3.</dt>
<dd>You MAY BECOME PREGNANT if you have sex in the <span class="Italics">7 days</span> after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up for those 7 days.</dd>
</dl>
<p>If you <span class="Bold">MISS 2</span> [white] "active" pills in a row in <span class="Bold">THE 3rd WEEK:</span></p>
<dl>
<dt>1.</dt>
<dd> <span class="Italics">If you are a Day 1 Starter:</span><br> THROW OUT the rest of the pill pack and start a new pack that same day.<br> <span class="Bold"><span class="Italics">If you are a Sunday Starter:</span></span><br> Keep taking 1 pill every day until Sunday.<br>On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day.</dd>
<dt>2.</dt>
<dd>You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant.</dd>
<dt>3.</dt>
<dd>You MAY BECOME PREGNANT if you have sex in the <span class="Italics">7 days</span> after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up for those 7 days.</dd>
</dl>
<p>If you <span class="Bold">MISS 3 OR MORE</span> [white] "active" pills in a row (during the first 3 weeks):</p>
<dl>
<dt>1.</dt>
<dd>
<span class="Bold"><span class="Italics"> If you are a Day 1 Starter:</span></span><br>THROW OUT the rest of the pill pack and start a new pack that same day.<br><span class="Bold"><span class="Italics">If you are a Sunday Starter:</span></span><br>Keep taking 1 pill every day until Sunday.<br>On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day.</dd>
<dt>2.</dt>
<dd>You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant.</dd>
<dt>3.</dt>
<dd>You MAY BECOME PREGNANT if you have sex in the <span class="Italics">7 days</span> after you miss pills. You MUST use another birth control method (such as condoms or foam) as a back-up for those 7 days.</dd>
</dl>
<p><span class="Bold">A REMINDER FOR THOSE ON 28 DAY PACKS</span></p>
<p>If you forget any of the 7 [light-green colored] "reminder" pills in WEEK 4: </p>
<p>THROW AWAY the pills you missed.</p>
<p>Keep taking 1 pill each day until the pack is empty.</p>
<p>You do not need a back-up method if you start your next pack on time.</p>
<p><span class="Bold">FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED:</span></p>
<p>Use a BACK-UP METHOD anytime you have sex. </p>
<p>KEEP TAKING ONE PILL EACH DAY until you can reach your doctor or clinic.</p>
<p><span class="Bold">PREGNANCY DUE TO PILL FAILURE</span></p>
<p>The incidence of pill failure resulting in pregnancy is approximately less than 1% if taken every day as directed, but more typical failure rates are less than 3%. If failure does occur, the risk to the fetus is minimal. </p>
<p><span class="Bold">RISKS TO THE FETUS</span></p>
<p>If you do become pregnant while using oral contraceptives, the risk to the fetus is small, on the order of no more than one per thousand. You should, however, discuss the risks to the developing child with your doctor. </p>
<p><span class="Bold">PREGNANCY AFTER STOPPING THE PILL</span></p>
<p>There may be some delay in becoming pregnant after you stop using oral contraceptives, especially if you had <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">irregular menstrual cycles</span> before you used oral contraceptives. It may be advisable to postpone conception until you begin menstruating regularly once you have stopped taking the pill and desire pregnancy. </p>
<p>There does not appear to be any increase in <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in newborn babies when pregnancy occurs soon after stopping the pill. </p>
<p><span class="Bold">OVERDOSAGE</span></p>
<p>Serious ill effects have not been reported following ingestion of large doses of oral contraceptives by young children. Overdosage may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> in females. In case of overdosage, contact your healthcare provider or pharmacist. </p>
<p><span class="Bold">OTHER INFORMATION</span></p>
<p>Your healthcare provider will take a medical and family history before prescribing oral contraceptives and will examine you. The physical examination may be delayed to another time if you request it and the healthcare provider believes that it is appropriate to postpone it. You should be reexamined at least once a year. Be sure to inform your healthcare provider if there is a family history of any of the conditions listed previously in this leaflet. Be sure to keep all appointments with your healthcare provider, because this is a time to determine if there are early signs of side effects of oral contraceptive use. </p>
<p>Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not give it to others who may want birth control pills. </p>
<p><span class="Bold">HEALTH BENEFITS FROM ORAL CONTRACEPTIVES</span></p>
<p>In addition to preventing pregnancy, use of oral contraceptives may provide certain benefits. They are:</p>
<dl>
<dt>•</dt>
<dd>Menstrual cycles may become more regular.</dd>
<dt>•</dt>
<dd>Blood flow during menstruation may be lighter, and less iron may be lost. Therefore, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> due to <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span> is less likely to occur.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> or other symptoms during menstruation may be encountered less frequently.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">Ovarian cysts</span> may occur less frequently.</dd>
<dt>•</dt>
<dd>Ectopic (tubal) pregnancy may occur less frequently.</dd>
<dt>•</dt>
<dd>Noncancerous <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> or lumps in the breast may occur less frequently.</dd>
<dt>•</dt>
<dd>Acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> may occur less frequently.</dd>
<dt>•</dt>
<dd>Oral contraceptive use may provide some protection against developing two forms of cancer: cancer of the ovaries and cancer of the lining of the uterus. </dd>
</dl>
<p>If you want more information about birth control pills, ask your doctor or pharmacist. They have a more technical leaflet called the Professional Labeling which you may wish to read.</p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].</p>
<p>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</p>
<p>All brand names listed are the registered trademarks of their respective owners and are not trademarks of Teva Pharmaceuticals USA.</p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA</span><br>Sellersville, PA 18960</p>
<p>Iss. 11/2013</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_0c84754e-ed00-4d23-a7ba-7a63cfee14af"></a><a name="section-14"></a><p></p>
<h1>Package/Label Display Panel</h1>
<div class="Figure">
<a name="id1430"></a><img alt="N:\SHARE\DrugList\Alpha Products\Cryselle 075840\_Labels\Foil Pouch (100646 Iss. 11-2013) FDA.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ee6be128-d494-4361-9a0d-341c0eee3587&amp;name=143d035e-f885-4ca9-a37c-b43e26c65aeb-06.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7714b104-d24b-4552-b3f6-9052ba29e755"></a><a name="section-14.1"></a><p></p>
<h2>Cryselle (norgestrel and ethinyl estradiol tablets USP) 0.3mg/0.03mg Pouch Label Text</h2>
<p class="First"><span class="Bold">NDC</span> 0555<span class="Bold">-9049-</span>58</p>
<p><span class="Bold">Cryselle<span class="Sup">®</span></span></p>
<p><span class="Bold">(norgestrel and</span></p>
<p><span class="Bold">ethinyl estradiol tablets USP)</span></p>
<p><span class="Bold">0.3mg/0.03 mg</span></p>
<p><span class="Bold">Contents:</span> One <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card dispenser of 28 tablets</p>
<p>Twenty-one white tablets, each containing 0.3 mg norgestrel with 0.03 mg</p>
<p>ethinyl estradiol and seven light-green inert tablets.</p>
<p><span class="Bold">THIS PRODUCT (LIKE ALL ORAL CONTRACEPTIVES) IS INTENDED TO </span></p>
<p><span class="Bold">PREVENT PREGNANCY.  IT DOES NOT PROTECT AGAINST <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV INFECTION</span> </span></p>
<p><span class="Bold">(AIDS) AND OTHER <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">SEXUALLY TRANSMITTED DISEASES</span>.</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">SHAPING</span></p>
<p><span class="Bold">WOMEN'S HEALTH<span class="Sup">®</span></span></p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CRYSELLE 		
					</strong><br><span class="contentTableReg">norgestrel and ethinyl estradiol kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0555-9049</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0555-9049-58</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem"> </td>
<td class="formItem">21 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem"> </td>
<td class="formItem">7 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>CRYSELLE 		
					</strong><br><span class="contentTableReg">norgestrel and ethinyl estradiol tablet, film coated</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NORGESTREL</strong> (NORGESTREL) </td>
<td class="formItem">NORGESTREL</td>
<td class="formItem">0.3 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ETHINYL ESTRADIOL</strong> (ETHINYL ESTRADIOL) </td>
<td class="formItem">ETHINYL ESTRADIOL</td>
<td class="formItem">0.03 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">dp;543</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075840</td>
<td class="formItem">07/24/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>INERT 		
					</strong><br><span class="contentTableReg">inert tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN (light-green) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">dp;331</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075840</td>
<td class="formItem">07/24/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075840</td>
<td class="formItem">07/24/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Barr Laboratories Inc.
							(802716563)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>143d035e-f885-4ca9-a37c-b43e26c65aeb</div>
<div>Set id: ee6be128-d494-4361-9a0d-341c0eee3587</div>
<div>Version: 3</div>
<div>Effective Time: 20140606</div>
</div>
</div> <div class="DistributorName">Barr Laboratories Inc.</div></p>
</body></html>
